Sublocade improves abstinence and quality of life outcomes

Treatment with injectable subcutaneous buprenorphine (Sublocade) over a course of a year resulted in better abstinence and quality of life, according to a study by Walter Ling and colleagues published in the current issue of the Journal of Addiction Medicine.